Novel Antibody May Reduce Amyloid, Cut AD Symptoms
Lecanemab can reduce amyloid plaques within the first months after treatment initiation and is linked to improved clinical signs in as early as 6 months, updates from a phase 2 trial show.
United States Fernando Testai American Academy Of Neurology Eisai Pharmaceuticals University Of Illinois At Chicago Chad Swanson
Source: medscape.com